AstraZeneca Reports 11% Revenue Growth, Reaffirms $80B 2030 Goal Despite China Headwinds
AZN•Through nine months of 2025, AstraZeneca grew revenue 11% and core EPS 15%, driven by 16% oncology, 8% biopharma and 6% rare disease gains. Management reiterated its $80 billion 2030 revenue target and guided high single-digit sales and low double-digit EPS growth in 2026 despite China tender headwinds.
1. Strong 2025 Commercial Performance and Near-Term Outlook
Chief Financial Officer Aradhana Sarin reported that AstraZeneca achieved total revenue growth of 11% and core EPS expansion of 15% over the first nine months of 2025. Oncology led therapy-area gains with a 16% increase, biopharmaceuticals rose 8% and rare disease climbed 6%, driven by newer medicines offsetting losses of exclusivity on mature brands such as Brilinta, Pulmicort and Soliris. Regionally, the U.S. delivered 11% growth while emerging markets outside China surged 21%. Management reaffirmed guidance for high single-digit revenue growth and low double-digit core EPS expansion at constant exchange rates, though flagged fourth-quarter headwinds from volume-based procurement in China and the timing of emerging-market tenders, as well as a tougher year-on-year comparison due to over $800 million of collaboration milestones recognized in Q4 2024. Full-year results are scheduled for Feb. 10.
